Medical Device Firm Remedy Lists on South Korea's Kosdaq on July 13 Amid 1701:1 Subscription Ratio

According to Seoul Economy, medical device manufacturer Remedy debuted on South Korea's Kosdaq market on July 13 with an offer price of 20,700 Korean won, at the upper end of its target range. The stock recorded a 1701:1 subscription ratio during public bidding from July 1-2, with institutional demand reaching 1146:1. The debut-day trading range is projected between 12,420 won and 82,800 won.

HL Genomics, a raw pharmaceutical manufacturer, is conducting public share subscription on July 13-14 with a final offer price of 21,500 won, set at the upper end of its target range. The company is scheduled to list on Kosdaq on July 24. Remedy develops portable X-ray imaging devices and non-destructive testing solutions for medical and industrial applications.